Female sexual interest drug reaches tipping point with Phase III plans
Pharmaceutical Technology
OCTOBER 10, 2022
In 2015, the FDA approved Sprout Pharmaceuticals’s Addyi, also known under the generic name flibanserin, for use by pre-menopausal women with hypoactive sexual desire disorder (HSDD). Moreover, despite the buzz generated when Addyi was launched in 2015, only one other drug has since been marketed.
59 
Let's personalize your content